Hormone profiling in a novel enteroendocrine cell line pGIP/neo: STC-1

KV Hand, L Giblin, BD Green - Metabolism, 2012 - Elsevier
KV Hand, L Giblin, BD Green
Metabolism, 2012Elsevier
OBJECTIVE.: GIP is a peptide hormone of therapeutic interest in type 2 diabetes and
obesity. This study evaluated pGIP/neo STC-1 as a potential K-cell model for studying GIP
secretion. METHODS.: We evaluated cellular storage and medium accumulation of GIP
along with other gastrointestinal peptides cholecystokinin (CCK), peptide YY (PYY),
obestatin and ghrelin over 72h and probed possible intracellular signals (PKA, PKC, Ca2+
and GPCR) involved in peptide hormone synthesis/secretion. RESULTS.: Results …
OBJECTIVE
GIP is a peptide hormone of therapeutic interest in type 2 diabetes and obesity. This study evaluated pGIP/neo STC-1 as a potential K-cell model for studying GIP secretion.
METHODS
We evaluated cellular storage and medium accumulation of GIP along with other gastrointestinal peptides cholecystokinin (CCK), peptide YY (PYY), obestatin and ghrelin over 72h and probed possible intracellular signals (PKA, PKC, Ca2+ and GPCR) involved in peptide hormone synthesis/secretion.
RESULTS
Results demonstrate for the first time that pGIP/Neo STC-1 cells produce and secrete 3 to 6 times more GIP than STC-1. The cells clearly retain the ability to synthesize and secrete CCK and PYY but reduced levels indicate a shift towards a predominantly K-cell phenotype. Furthermore, gastric peptides such as obestatin and ghrelin are not produced in either STC-1 or pGIP/Neo STC-1 cells.
DISCUSSION
This study demonstrates the potential usefulness of pGIP/Neo cells for studying GIP secretion and further investigations will establish its suitability for investigating hormone release in vitro.
Elsevier